Source:http://linkedlifedata.com/resource/pubmed/id/10505108
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1999-10-22
|
| pubmed:abstractText |
We have utilized a nonviral, polymeric interactive non-condensing (PINC) gene delivery system to deliver IL-12 to two different types of murine tumors, an immunogenic renal cell carcinoma, Renca, and a non-immunogenic colon cell carcinoma, CT26. The delivery of IL-12/polyvinyl pyrrolidone (PVP) complexes into Renca led to the expression of IL-12 (146 +/- 89 pg/mg) and IFN-gamma (160 +/- 82 pg/mg) from explanted tumors in culture supernatants. Treated tumors showed increased infiltration of NK, CD4+ and CD8+ T cells and up-regulation of MHC class I molecules on leukocytes in both tumors and lymph nodes. Fifty per cent of tumor-bearing mice rejected Renca or CT26 tumors following IL-12/PVP treatments given at optimal doses of 24 and 48 micrograms, respectively. While polymorphonuclear cells (PMNs) were partially involved in the development of the antitumor immune response elicited by IL-12/PVP treatment, CD8+ T cells were found to be the primary effectors. In contrast, CD4+ T cells did not appear to play a significant role in the development of tumor specific immunity. Finally, mice that rejected the tumors following IL-12/PVP treatment were protected against a second challenge with the same tumor. These data provide evidence that a nonviral IL-12 gene delivery system is well tolerated and generates a potent immune response against established tumors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0969-7128
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
833-9
|
| pubmed:dateRevised |
2008-11-21
|
| pubmed:meshHeading |
pubmed-meshheading:10505108-Animals,
pubmed-meshheading:10505108-CD8-Positive T-Lymphocytes,
pubmed-meshheading:10505108-Carcinoma, Renal Cell,
pubmed-meshheading:10505108-Colonic Neoplasms,
pubmed-meshheading:10505108-Female,
pubmed-meshheading:10505108-Gene Expression,
pubmed-meshheading:10505108-Gene Therapy,
pubmed-meshheading:10505108-Genetic Vectors,
pubmed-meshheading:10505108-Immunotherapy, Active,
pubmed-meshheading:10505108-Injections, Intralesional,
pubmed-meshheading:10505108-Interferon-gamma,
pubmed-meshheading:10505108-Interleukin-12,
pubmed-meshheading:10505108-Kidney Neoplasms,
pubmed-meshheading:10505108-Mice,
pubmed-meshheading:10505108-Mice, Inbred BALB C,
pubmed-meshheading:10505108-Neoplasms, Experimental,
pubmed-meshheading:10505108-Tumor Cells, Cultured
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
|
| pubmed:affiliation |
GeneMedicine, Inc. The Woodlands, TX 77381-4248, USA.
|
| pubmed:publicationType |
Journal Article
|